SPA, Sparton Corporation

** SPA reported that it has been awarded a contract by Australia to manufacture the AN/SSQ-62E and AN/SSQ-53F sonobuoys. The award is valued at approximately $7.6 million and will be manufactured at SPA's De Leon Springs, FL facility for a May 2012 delivery.

SPA was previously awarded $9.7 million in contracts by Canada, Norway, and Brazil for the AN/SSQ-53F, AN/SSQ-62E, and AN/SSQ-36B sonobuoys which were delivered in the first half of SPA's current fiscal year.

The primary purpose of a sonobuoy is to detect acoustic emissions or reflections from potentially hostile submarines and transmit these signals to airborne antisubmarine warfare forces.

SPA is the only U.S.-owned designer and manufacturer of various sonobuoy products for the U.S. and other free-world nations.

SPA is a provider of complex and sophisticated electromechanical devices with capabilities that include concept development, industrial design, design and manufacturing engineering, production, distribution, field service, and refurbishment. The primary markets served are Medical, Military & Aerospace, and Industrial & Instrumentation.

More about SPA at www.sparton.com.

*****************

BLRX, BioLineRx Ltd.

** BLRX reported that it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C (a blood borne infection of the liver caused by the Hepatitis C virus (HCV) which becomes chronic in about 85% of cases).

The agreement includes upfront license fees, milestones and royalties payable to both companies, which terms are consistent with BLRX's standard in-license agreements.

BL-8030 is a potent and selective second generation NS3 protease inhibitor. The NS3 protease is essential for the replication of the Hepatitis C virus (HCV) and is an important target for HCV therapies.

BLRX, a biopharmaceutical development company, is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies.

More about BLRX at www.biolinerx.com.

*****************

SURW, SureWest Communications

** Consolidated Communications Holdings, Inc. and SURW reported that they have entered into a definitive agreement under which Consolidated will acquire all the outstanding shares of SURW in a cash and stock transaction valued at $23.00 per share, or a total of approximately $340.9 million, exclusive of debt.

SURW is a leading integrated communications provider and the bandwidth leader in the markets it serves. SURW offers bundled residential and commercial services in the greater Sacramento and Kansas City regions that include IP-based digital and high-definition television, high-speed Internet, Voice over IP, and local and long distance telephone.

More about SURW at www.surw.com

**************************************************************

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.